Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

NCT06327815 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

633

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
DRUG: Dapagliflozin tablets and Metformin HCl extended-release tablets

Sponsor

AstraZeneca